1365 An immunocytokine with target cell-restricted IL-15 activity for induction of anti-tumor immunity against acute myeloid leukemia

1365 An immunocytokine with target cell-restricted IL-15 activity for induction of anti-tumor immunity against acute myeloid leukemia

Bibliographic Details
Main Authors:	Melanie Märklin, Gundram Jung, Martin Pflügler, Helmut R Salih, Latifa Zekri, Martina S Lutz, Bastian Schmied, Fabian Riegg
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia
by: Fabian Riegg, et al.
Published: (2021-04-01)

An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity Against Colorectal Cancer
by: Bastian J. Schmied, et al.
Published: (2019-06-01)

1390 A Fc-optimized B7-H3 antibody for induction of NK cell reactivity against acute myeloid leukemia
by: Melanie Märklin, et al.
Published: (2023-11-01)

B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma
by: Ilona Hagelstein, et al.
Published: (2022-10-01)

Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody
by: Sylwia A. Stefańczyk, et al.
Published: (2024-04-01)

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
by: Melanie Märklin, et al.
Published: (2019-05-01)

CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
by: Joseph Kauer, et al.
Published: (2021-09-01)

Immunocytokines
by: Katrin L. Gutbrodt, et al.
Published: (2012-05-01)

Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia
by: Maddalena Marconato, et al.
Published: (2022-09-01)

DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis
by: Anna Chashchina, et al.
Published: (2021-09-01)

1366 B7-H3xCD3 bispecific antibody as novel treatment option in HER2-negative breast cancer
by: Ilona Hagelstein, et al.
Published: (2023-11-01)

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
by: Martina S. Lutz, et al.
Published: (2023-04-01)

Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
by: Latifa Zekri, et al.
Published: (2023-03-01)

Utilizing Immunocytokines for Cancer Therapy
by: Erin Runbeck, et al.
Published: (2021-03-01)

A history of Johore (1365-1895)
by: Winstedt, Richard Olof, Sir, 1878-, et al.

A History of Johore 1365-1895 /
by: Winstedt,Richard Olof, Sir, 1878-1966, author
Published: (2020)

A history of Johore (1365-1941) /
by: Winstedt, Richard Olof, Sir, 1878-, et al.
Published: (1992)

A history of Johore (1365-1895) /
by: Winstedt, Richard Olof, Sir, 1878- 349514, et al.
Published: (1979)

An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer
by: Martina S. Lutz, et al.
Published: (2024-01-01)

Immunocytokines with activity-on-demand by combination with small molecule inhibitors
by: Dafne Müller
Published: (2024-03-01)

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
by: Tzeng, Alice, et al.
Published: (2015)

NHS-IL12, a Tumor-Targeting Immunocytokine
by: Greiner JW, et al.
Published: (2021-05-01)

IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases
by: Sebastian Hörner, et al.
Published: (2022-08-01)

Immunocytokines: a review of molecules in clinical development for cancer therapy
by: List T, et al.
Published: (2013-08-01)

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas
by: Ilona Hagelstein, et al.
Published: (2021-04-01)

1353 An Fc-optimized B7-H3-targeting antibody for treatment of ovarian cancer
by: Ilona Hagelstein, et al.
Published: (2023-11-01)

An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
by: Latifa Zekri, et al.
Published: (2021-02-01)

Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine
by: Christine M. Minnar, et al.
Published: (2024-01-01)

Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy
by: Keunok Jung, et al.
Published: (2022-10-01)

965 NFAT2 drives the cytoskeletal remodeling of leukemia cells, which regulates their vulnerability to perforin-mediated killing
by: Melanie Märklin, et al.
Published: (2023-11-01)

The challenges of translation
by: Helmut R Salih, et al.
Published: (2019-12-01)

1159 A targeted masked ImmunoCytokine for CD138 expressing cancers
by: Ryan Trinh, et al.
Published: (2023-11-01)

The Study of Frequency and Causes of Amputation of Limbs in Hamadan City from 1365 to 1374
by: Amir Keshvarei, et al.
Published: (1997-03-01)

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
by: Christian Klein, et al.
Published: (2017-03-01)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
by: Melanie Märklin, et al.
Published: (2022-03-01)

A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors
by: Giulia Rotta, et al.
Published: (2024-03-01)

Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL)
by: Kübra Kaban, et al.
Published: (2021-11-01)

The hard X-ray spectrum of NGC 1365: scattered light, not black hole spin
by: Miller, L, et al.
Published: (2013)

Clinical and Histopathological Characteristics of Tumors Arising in Seborrheic Keratosis: A Study of 1365 Cases
by: Ye Q, et al.
Published: (2021-10-01)

Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma.
by: Melissa Paoloni, et al.
Published: (2015-01-01)